EGFR and LGR5 Dual-Targeting Antibody-Drug Conjugate-Based Therapeutic Strategies for the Improved Treatment of Colorectal Cancer

作者
Peyton C. High
链接
摘要

Despite significant efforts, colorectal cancer (CRC) prognosis remains poor, exemplifying a need for improved therapies. Antibody-drug conjugates (ADCs) are a rapidly expanding class of therapeutics that utilize antibody-mediated specificity for a target antigen overexpressed on the tumor surface to deliver highly potent drug payloads to cancer cells while sparing normal tissues. Here, we describe the development of a novel topoisomerase I inhibitor-conjugated ADC (8E11-CPT2) targeting leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), a marker of cancer stem-like cells highly overexpressed in CRC, that elicits dose- and target-dependent cytotoxicity with minimal toxicity. Furthermore, we demonstrate that cetuximab (CTX), a mAb targeting the epidermal growth factor receptor (EGFR) that is FDA-approved for KRASWT mCRC, increases LGR5 levels independent of KRAS mutation. Importantly, combination treatment of CTX and 8E11-CPT2 significantly reduces tumor burden and extends survival in RASMUT CRC patient-derived xenografts as compared to monotherapies. Having validated EGFR and LGR5 dual therapeutic targeting as an effective strategy, we then generated two EGFR:LGR5 bispecific antibodies (bsAbs; E⨯L-1 and E⨯L-2) that drive EGFR lysosomal degradation in an LGR5-driven manner. Furthermore, we produced an EGFR:LGR5 bsADC (E⨯L-1-CPT2) that demonstrates significantly enhanced cytotoxicity in EGFR- and LGR5-expressing cancer cell lines and superior anti-tumor efficacy in CRC xenografts as compared to E⨯L-1 bsAb and 8E11-CPT2 LGR5 ADC. Taken together, this work strongly rationalizes dual-targeting of EGFR and LGR5 for CRC and is in line with growing evidence that multi-targeting therapeutic strategies may prove more effective in treating cancer than single target-based approaches.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lin的应助被学术bug采纳,获得10
刚刚
一诺相许发布了新的文献求助10
刚刚
justonce发布了新的文献求助10
1秒前
zorro3574完成签到,获得积分10
2秒前
moran完成签到 ,获得积分10
3秒前
Zz发布了新的文献求助200
4秒前
cdercder的应助被开心德地采纳,获得10
5秒前
水煮电吹风的应助被liu采纳,获得10
6秒前
海阔天空发布了新的文献求助10
6秒前
酷波er的应助被小燕尾条采纳,获得10
7秒前
单薄冰安发布了新的文献求助10
8秒前
8秒前
常濪完成签到 ,获得积分10
10秒前
CipherSage的应助被yu采纳,获得10
10秒前
大庆完成签到,获得积分10
12秒前
研友_VZG7GZ的应助被温暖砖头采纳,获得10
13秒前
33333完成签到,获得积分10
13秒前
春桑早点睡完成签到,获得积分10
14秒前
超超发布了新的文献求助10
15秒前
16秒前
徵宇完成签到,获得积分10
16秒前
17秒前
GL完成签到,获得积分10
18秒前
Mine完成签到,获得积分20
18秒前
深情安青的应助被dididi采纳,获得10
18秒前
安赛虫完成签到,获得积分10
19秒前
xing完成签到,获得积分10
20秒前
CipherSage的应助被hefang采纳,获得10
20秒前
yu发布了新的文献求助10
21秒前
cdercder的应助被开心德地采纳,获得10
21秒前
贾贡献的应助被学术bug采纳,获得10
22秒前
yyf完成签到,获得积分10
22秒前
22秒前
森煜完成签到,获得积分10
24秒前
所所的应助被幽默的羿采纳,获得10
25秒前
26秒前
加油完成签到,获得积分10
26秒前
Fun_112发布了新的文献求助30
26秒前
一十七完成签到 ,获得积分10
28秒前
顾矜的应助被淡淡新竹采纳,获得10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188724
求助须知:如何正确求助?哪些是违规求助? 9576405
关于积分的说明 21847400
捐赠科研通 7786785
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559647
邀请新用户注册赠送积分活动 2482363